We are pleased to announce the launch of the Parkwalk Knowledge Intensive EIS Fund III, an HMRC-approved EIS Fund. As featured in Investment Week, the third Knowledge Intensive Fund will back cutting-edge technology companies spun out of leading UK universities and research institutions, mirroring the investment strategy of our Opportunities EIS Fund. Parkwalk Advisors, the
We are delighted to announce that our University of Oxford Innovation Fund VI is now closed, surpassing its target and raising £3m. As featured in an article by UKTN, the Fund is run in conjunction with Oxford University Innovation, backing cutting-edge technology and science spin-outs from the University of Oxford. Oxford University Innovation and Parkwalk
Parkwalk is pleased to announce that portfolio company, Mogrify, have extended their Series A financing to $46m USD. The University of Cambridge and University of Bristol spinout is enabling the next generation of gene sequencing and gene-regulatory data to help transform the lives of patients living with degenerative diseases. This funding round aims to support
Parkwalk have launched our annual ‘Equity Investments into Spinouts’ 2023 report, in conjunction with Beauhurst. The report findings also feature in the Financial Times, “Investment in UK university spinouts falls after decade of growth“ article, where Moray Wright, CEO, Parkwalk, calls for further action to channel more UK investment into high-potential spinouts. Download the ‘Equity
Parkwalk are delighted to announce the acquisition of our portfolio company PetMedix, generating a positive return for our EIS investors. PetMedix, a leader in discovering species-specific therapeutic antibodies for pets, announced that it has been acquired by the world’s leading animal health company. In addition to successful research collaborations, PetMedix’s proprietary drug development activities have
We are delighted to announce our latest investment into Phasecraft as part of a £13m Series A Funding Round. The University College London spin-out designs quantum software for quantum information processors encompassing both near-term intermediate-scale devices and universal fault-tolerant computers. This latest funding round will help the company to develop Phasecraft’s quantum algorithms to the point of practical
Parkwalk is thrilled to announce our latest investment into Entia as part of a $20m series A funding round to launch the world’s most comprehensive monitoring solution for patients undergoing cancer therapy. Healthtech company Entia has closed a successful $20m Series A financing round. The round was led by BGF and Parkwalk plus other existing investors, with
Concr is a value-driven techbio company, spun out of the University of Cambridge, applying statistical learning and advanced modelling adopted from astrophysics to aid in the precision treatment of cancer patients. Concr’s online platform allows the storage, management and analysis of data generating actionable insights for cost-effective drug development and patient treatment.
We are delighted to announce the launch of our University of Oxford Innovation Fund (UOIF) VI. The fund is managed by Parkwalk, in conjunction with the University of Oxford’s Technology Transfer Office, Oxford University Innovation. The Fund invests in early-stage hard science and deep-tech companies, spun-out of the University of Oxford, the UK’s largest research-based
On Wednesday 7th June 2023, we held our annual Portfolio Showcase at the Royal Society of Chemistry, showcasing innovative companies from our portfolio. The portfolio showcase brought together 20 of our ground-breaking EIS investment companies from the UK’s top universities, including the Golden Triangle; Cambridge, Oxford and London. The evening was a great success, with
Parkwalk is delighted to announce Oxbotica’s rebranding to Oxa, marking the next stage in the company’s growth as it prepares to scale in North America and Europe. Oxa has developed autonomous vehicle software that operates anywhere without dependence on external systems such as GPS and third-party maps. Oxa’s journey has been exciting to watch and
Parkwalk announces our recent funding round into new portfolio company AccelerComm. The University of Southampton spin-out has developed patented communication algorithms for 5G, doubling network capacity whilst halving power consumption and slashing latency. The company’s patent-protected solutions offer a complete physical layer of IP solutions enabling optimal performance for 5G radio access networks. This latest
Parkwalk is delighted to announce that, in a first for the graphene electronics industry, leading integrated device manufacturer Paragraf is acquiring graphene biosensor market pioneer Cardea Bio to accelerate the mass production of a new generation of devices that will deliver real-time analysis in point-of-need tests in the agritech, healthcare and environmental monitoring spaces. SOMERSHAM,
We are delighted to announce our latest investment into Wayland Additive, as part of a £4.6m funding round. This latest investment will increase Wayland’s in-house production capability delivering more machines and materials to its customers, whilst expanding its team to support further R&D. Huddersfield-based Wayland Additive Limited, an electron beam 3D printing manufacturer has raised £4.6
OSSTEC is an Imperial College spin-out which has developed a bone healing technology to improve patient care from the lab to the operating room. Their additive manufactured bone healing platform technology will look to change orthopaedics by keeping patients healthy and active.
Accelercomm is a leader in high-performance wireless communications solutions. The University of Southampton spin-out has developed patented communications algorithms for 5G, doubling network capacity whilst halving power consumption and slashing latency. Accelercomm’s patent-protected solutions offer a complete physical layer IP solution enabling optimal performance for 5G radio access networks.
This website and the Investor Portal are operated by Parkwalk Advisors Ltd (“Parkwalk“, “we“, or us“). In this Privacy Notice, we explain how we handle personal information about our investors, potential investors and where relevant, their independent financial advisers (“IFAs”) (together, “Investors“) and any users of this website (“Website Users“). It also provides details of
Thrilled to see our CEO, Moray Wright, featured in Business Weekly’s article, discussing technology funding and the UK’s economic ecosystems, especially pension funds. The government’s aim to develop the UK into a science superpower is focused around investment in the five technologies of tomorrow, areas in which Parkwalk has plenty of experience: quantum, AI, engineering,
To mark the end of Healthcare Science Week, we discuss the value and impact of investing in genomics. We also give examples of some ground-breaking genomic companies Parkwalk has invested in. Defined by NHS England, genomics is the study of all genes encoded in our DNA, how they function and their influence on growth and
We are thrilled to announce our recent investment in Legislate, as part of a $3.6m funding round. The company has designed a legal SaaS platform that allows for non-lawyers to safely create, manage and search lawyer-approved contracts. This latest funding round will allow businesses with hundreds of contracts to query and compare terms using its
